Treatment of chronic gout. A new approach to an old problem;Tratamiento de la gota cronica. Una nueva aproximacion a un antiguo problema

Revista Espanola de Reumatologia

Volumn 26, Issue 1, 1999, Pages 21-25

  Pérez Ruiz, Fernando ^a   Calabozo Raluy, Marcelo ^a   Alonso Ruiz, Alberto ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; GOUT; HUMAN; MEDICAL RESEARCH; REVIEW; TREATMENT PLANNING;

EID: 0033023892     PISSN: 03044815     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Yu TF, Gutman AB. Principles of current management of primary gout. Arn J Med Sci 1967; 254: 893-907.
2. Sorensen LB. The pathogenesis of gout. Arch Intern Med 1962; 109: 55-66.
3. Yu TF. Milestones in the treatment of gout. Am J Med 1974; 56: 676-85.
4. Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis 1983; 42 (Supl): 12-5.
5. Emmerson BT. The management of gout. N Engl J Med 1996; 334: 445-51.
6. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991; 34: 141-5.
7. Nakayama DA, Barthelemy C, Carrera C, Lightfoot RW Jr, Wortman RL. Tophaceous gout. A clinical and radiographic assessment. Arthritis Rheum 1984; 27: 468-71.
8. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989; 16: 1.246-8.
9. McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991; 34: 1.489-94.
10. O'Reilly S, Doherty M. Missed opportunity following diagnosis of gout. Ann Rheum Dis 1995; 54: 86-7.
11. Schleshinger N, Baker DG, Schumacher HR. Jr. Serum urate during bouts of acute gouty arthritis. J Rheumatol 1997; 24: 2 265-6.
12. Pérez-Ruiz F, Calabozo M, Alonso-Ruiz A. Gouty arthritis in the manubriosternal joint. Ann Rheum Dis 1997; 56: 571.
13. Muǹoz Sanz A, García Puig J, Mateos Antón F, Pérez Miranda M, Ortiz Vázquez J. Estudio farmacolögico del gobierno renal excretor de ácido úrico en la gota primaria del adulto. Nefrología 1983; 3: 17-21.
14. Garcia Puig J, Mateos Antón F, Conthe P, Muñoz Sanz A, Gaspar G, Herrero E et al. Gobierno renal excretor de uratos en pacientes con gota primaria. An Med Intern 1986; 3: 3-10.
15. Pérez-Ruiz F, Alonso-Ruiz A, Calabozo M, Ruiz-Lucea E, Aretxabala J, Fraiz E. Análisis de los métodos para la clasificación de la gota. Rev Esp Reumatol 1997; 5: 154.
16. Kaufman JM, Greene ML, Seegmiller JE. Urine acid to creatinine ratio -a screening test for inherited disorders of purine metabolism. J Pediatr 1968; 73: 583-92.
17. Simkin PA, Hoover PL, Paxon CS, Wilson WF. Uric acid excretion: quantitative assessment from spot, midmorning serum and urine samples. Ann Intern Med 1979; 91: 44-7.
18. Wortman RL, Fox IH. Limited value of uric acid to creatinine ratios in estimating uric acid excretion. Ann Intern Med 1980; 93: 822-5.
19. Pérez-Ruiz F, Calabozo M, Alonso-Ruiz A, Herrero-Beites A. Analysis of the methods for the classification of renal handling of urate in gout. Arthritis Rheum 1997; 40 (Supl): 48.
20. Riesselbach RE, Steele TH. Influence of the kidney upon urate homeostasis in health and disease. Am J Med 1974; 56: 665-753.
21. Berger L, Yu RF. Renal function in gout. Am J Med 1975; 605-13.
22. Kelley WN. Treatment of hyperuricemia. En: McCarthy DJ, editor. Arthritis and allied conditions. A textbook of rheumatology. Filadelfia: Lea & Febiger, 1979; 1.229-44.
23. Simkin PA. Management of gout. Ann Intern Med 1979; 90: 812-6.
24. Rosenthal AK, Ryan LM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am 1995; 21: 151-61.
25. Pawlotsky Y. Treatment of gout. Rheumatol Eur 1996; 25: 142-4.
26. Loebl Wy, Sctt JT. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974; 33: 304-7.
27. Gast LF. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. Clin Rheumatol 1987; 6: 70-3.
28. Van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of long-term antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993; 20: 1.383-5.
29. Pérez-Ruiz F, Alonso-Ruiz A, Calabozo M, Ruiz-Lucea E, Aretxabaleta I, Fraiz E. Comparative study of the efficacy of benzbromarone and allopurinol for the therapy of hyperuricemia in chronic primary gout. Arthritis Rheum 1996; 39 (Supl): 86.
30. Wolfe F, Cathey MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol 1991; 18; 1.232-4.
31. Ferraz MB. An evidence based appraisal of the management of nontophaceous interval gout. J Rheumatol 1995; 22: 1.618-20.
32. Fam AG. Should patients with interval gout be treated with urate following drugs? J Rheumatol 1995; 22: 1.621-3.
33. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995; 22: 908-14.
34. Harris CM, Lloyd DCEF, Lewis J, The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995; 48: 1.153-8.
35. Nicholls A, Scott JT. Effect of weight-loss on plasma and urinary levels of uric acid. Lancet 1972; 1.223-4.
36. Ralston SH, Capell HA, Sturrock RD. Alcohol and response to treatment of gout. Br Med J 1988; 296: 1.641-2.
37. Schumacher RH. Jr. Crystal-induced arthritis: an overview. Am J Med 1996; 100 (Supl 2A): 46-52.
38. Hande KR, Noone RM, Stone WJ. Severe allopuririol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56.
39. Pérez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benztromerone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545-9.
40. WHO Collaboratory Center for Drug Statistics Methodology-Anatomical therapeutic chemical (TAC) classification index. Including defined daily dosis (DDDs) for plain substances. Oslo: WHO, 1993.
41. Scott JT. Long-term management of gout and hyperuicemia. Br Med J 1980; 281: 1.164-6.
42. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arhtritis Rheum 1986; 29: 82-7.
43. Boston Collaborative Drug Surveillance Program. Excess of ampicillin rashes associated with alopurinol or hyperuricemia. N Engl J Med 1972; 286: 505-7.
44. Marcen R, Gallego N, Orofino L, Gámez C, Estempa MR, Sabater J et al. Impaiment of tubular secretion of urate in renal tansplant patients on cyclosporin. Nephron 1995; 70: 307-313.
45. Zürcher RM, Bock HA. Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994; 9: 548-51.
46. Cummings D, Sekar M, Halil O, Banner N. Myelosupression associated with azathioprine-allopurinol interaction after heart and lung Transplantation 1996; 61: 1.161-2.
47. Pérez-Ruiz F, Calabozo M, Alonso-Ruiz A. Treatment of gout after transplantation. Br J Rheum 1998; 37: 580.
48. Asplin JR. Uric acid stones. Semin Nephrol 1996; 16: 412-24.
49. Khatchadourian J, Preminger GM, Whitson PA, Adams-Huet B, Pak CYC. Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation. J Urol 1995; 154: 1.665-9.
50. Pérez-Ruiz F, Calabozo M, Fernández-López MJ, Herrero-Beites A, Ruiz-Lucea E, García-Erauskin G, Dumelo J, Alonso-Ruiz A. Treatment of chronic gout in patients with renal fuction impairment. An Open, randomised, actively controlled study. J Clin Rheum (en prensa).